Chiusura precedente | 15,04 |
Aperto | 15,02 |
Denaro | N/D x N/D |
Domanda | N/D x N/D |
Min-Max giorno | 14,99 - 15,10 |
Intervallo di 52 settimane | 10,80 - 18,01 |
Volume | |
Media Volume | 17.371 |
Capitalizzazione | N/D |
Beta (mensile su 5 anni) | 0,27 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | N/D |
Prossima data utili | 01 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 October 2023 – 7:00 AM CET Continued strong third quarter performance with 11% topline growth to €191 million Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 30 September 2023. Key Highlights Solid revenue growth continues with 10.6% reported growth (13.9% at CER) and 10.2% organic growth (13.4% at CER) to €191.4 millionSustained
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 19 September 2023 – 6PM CET Fagron completes share buy-back program Fagron has successfully completed its share buy-back program today. In the last period, from 18 September 2023 through 19 September 2023, Fagron purchased 17,266 of its owns shares at an average price of €16.12 per share corresponding to a total amount of €277,612.81. A total of 138,372 Fagron shares have been repurchased under the buy-back program at an averag
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 15 September 2023 – 6PM CET Progress share buy-back program Fagron In the period from 11 September 2023 through 15 September 2023, Fagron purchased 27,000 of its owns shares at an average price of €16.81 per share corresponding to a total amount of €453,745.66. These purchases are part of the share buy-back program of up to 138,372 Fagron shares to fulfill Fagron’s obligations under its long term incentive scheme, which was ann